All In Biotech

Drug Trial Radar · NCT02944448

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Last checked: Nov 19, 2026Latest source record: Oct 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 761 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

761

Actual

Start

Sep 2016

Primary completion

May 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study schedule consists of a Screening Period (up to 14 days), a blinded 4- week Titration-to-Effect Period with weekly visits, a blinded 4-week Maintenance Treatment Period at the optimal dose level determined for each patient, and a 1-week Follow-up Period. Eligible patients will be randomized to receive either CR845 or placebo in a 2:1 ratio. Every patient will be started on a 1-mg dose of CR845 or matching placebo. During the post-randomization Titration-to-Effect period, the dose of study drug may be increased to 2.5 mg or 5 mg in a double-blind fashion. Patients may know their dose is being changed but will not know whether they were randomization to active study drug or placebo. Approximately 330 patients will be enrolled in this study.

Conditions

  • Osteoarthritis, Hip
  • Osteoarthritis, Knee
  • Arthritis
  • Joint Diseases
  • Musculoskeletal Diseases
  • Rheumatic Diseases

Interventions

  • CR845 tablet 1 mgDrug

    CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

  • CR845 tablet 2.5 mgDrug

    CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

  • CR845 tablet 5 mgDrug

    CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

  • Placebo tabletDrug

    Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline at Week 8 With Respect to the Weekly Mean of the Daily 24-hour Pain Intensity for the Index Joint as Measured by the Numeric Rating Scale (NRS).Time frame: Baseline, Week 8

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Birmingham, Alabama

  • Cara Therapeutics Study Site

    Peoria, Arizona

  • Cara Therapeutics Study Site

    Phoenix, Arizona

  • Cara Therapeutics Study Site

    Carmichael, California

  • Cara Therapeutics Study Site

    San Diego, California

  • Cara Therapeutics Study Site

    Tustin, California

  • Cara Therapeutics Study Site

    Homestead, Florida

  • Cara Therapeutics Study Site

    Jupiter, Florida

  • Cara Therapeutics Study Site

    Lake Worth, Florida

  • Cara Therapeutics Study Site

    Miami, Florida

  • Cara Therapeutics Study Site

    Oldsmar, Florida

  • Cara Therapeutics Study Site

    Orlando, Florida

  • Cara Therapeutics Study Site

    Plantation, Florida

  • Cara Therapeutics Study Site

    South Miami, Florida

  • Cara Therapeutics Study Site

    Tampa, Florida

  • Cara Therapeutics Study Site

    Savannah, Georgia

  • Cara Therapeutics Study Site

    Hazelwood, Missouri

  • Cara Therapeutics Study Site

    Omaha, Nebraska

  • Cara Therapeutics Study Site

    Las Vegas, Nevada

  • Cara Therapeutics Study Site

    Berlin, New Jersey

  • Cara Therapeutics Study Site

    Binghamton, New York

  • Cara Therapeutics Study Site

    Rochester, New York

  • Cara Therapeutics Study Site

    Cincinnati, Ohio

  • Cara Therapeutics Study Site

    Cincinnati, Ohio

  • Cara Therapeutics Study Site

    Oklahoma City, Oklahoma

  • Cara Therapeutics Study Site

    Duncansville, Pennsylvania

  • Cara Therapeutics Study Site

    Charleston, South Carolina

  • Cara Therapeutics Study Site

    Charleston, South Carolina

  • Cara Therapeutics Study Site

    Greenville, South Carolina

  • Cara Therapeutics Study Site

    Austin, Texas

  • Cara Therapeutics Study Site

    Dallas, Texas

  • Cara Therapeutics Study Site

    Plano, Texas

  • Cara Therapeutics Study Site

    Plano, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.